Immunomedics’ Phase III clivatuzumab battles pancreatic cancer pessimism, needs 2 months OS improvement

23 Feb 2016

Immunomedics' (NASDAQ:IMMU) clivatuzumab exhibits potential as a third-line therapy in pancreatic cancer, experts said, while noting that an overall survival (OS) of two months over the control arm would be clinically significant. Yet the slew of failed trials in this space warrants caution regarding Phase III success, they added.

Despite observed bone marrow toxicities, the safety profile and mechanism of action were lauded by experts in view of the dearth of options in the space. While, the complexity of the disease, along with a selection bias for healthier patients in smaller trials, has made it difficult for oncologists to predict Phase III trial success in larger randomized settings.

If successful as a later line option, clivatuzumab has the potential to be moved earlier in the treatment regimen, said one expert.

Positioning clivatuzumab as a third-line therapy would provide patients with another option to extend survival, and the therapy will hopefuly be well tolerated in this advanced setting, said Dr David Goldenberg, CSO, Immunomedics.

 
1 Start 2 Complete